Group 1 - The core viewpoint of the report is that Citibank reaffirms its "highly confident outperform" rating for CSPC Pharmaceutical Group (01093), raising the target price from HKD 17.4 to HKD 19 [1] - The bank anticipates that the business development (BD) transactions completed by CSPC will start converting into recurring revenue from this year [1] - CSPC has entered into four significant BD transactions with AstraZeneca (AZN.US) and Madrigal Pharmaceuticals (MDGL.US), expected to generate approximately USD 10.2 billion in upfront and milestone payments, significantly boosting profits from 2025 to 2027 to RMB 6.3 billion, RMB 10.2 billion, and RMB 10.9 billion respectively [1] Group 2 - The bank has adjusted its profit forecasts for CSPC for 2025 to 2027, decreasing the 2025 estimate by 2.4%, increasing the 2026 estimate by 8.2%, and increasing the 2027 estimate by 53.7%, reflecting the financial impact of the BD transactions after risk adjustments [1] - CSPC is currently trading at a forecasted price-to-earnings ratio of 9.2 times for 2026, significantly lower than the industry median of 16.4 times [1]
里昂：料石药集团BD交易将转化为经常性收入 升目标价至19港元